stoxline Quote Chart Rank Option Currency Glossary
Syros Pharmaceuticals, Inc. (SYRS)
4.97  -0.18 (-3.5%)    05-24 16:00
Open: 5.13
High: 5.21
Volume: 66,945
Pre. Close: 5.15
Low: 4.94
Market Cap: 133(M)
Technical analysis
2024-05-27 4:49:22 PM
Short term     
Mid term     
Targets 6-month :  6.26 1-year :  6.84
Resists First :  5.36 Second :  5.86
Pivot price 5.25
Supports First :  4.57 Second :  3.8
MAs MA(5) :  5.34 MA(20) :  5.27
MA(100) :  6.2 MA(250) :  4.62
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  27 D(3) :  48.1
RSI RSI(14): 41.5
52-week High :  8.17 Low :  2.08
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SYRS ] has closed above bottom band by 19.8%. Bollinger Bands are 40% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.22 - 5.25 5.25 - 5.28
Low: 4.87 - 4.91 4.91 - 4.94
Close: 4.92 - 4.98 4.98 - 5.02
Company Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Headline News

Sun, 26 May 2024
Will Syros Pharmaceuticals, Inc. (SYRS) Report Negative Q2 Earnings? What You Should Know - Yahoo Sport Australia

Tue, 21 May 2024
Assenagon Asset Management S.A. Has $909,000 Holdings in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) - MarketBeat

Tue, 07 May 2024
Syros to Participate in Upcoming Investor Conferences - Business Wire

Wed, 01 May 2024
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Wed, 10 Apr 2024
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML - Zacks Investment Research

Tue, 02 Apr 2024
Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 27 (M)
Held by Insiders 1.243e+007 (%)
Held by Institutions 1.3 (%)
Shares Short 1,820 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.2425e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -6 %
Return on Assets (ttm) 996.1 %
Return on Equity (ttm) -38.4 %
Qtrly Rev. Growth 9.94e+006 %
Gross Profit (p.s.) 0
Sales Per Share -130.26
EBITDA (p.s.) 0
Qtrly Earnings Growth -5.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -110 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 13.8
Stock Dividends
Dividend 0
Forward Dividend 1.45e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android